A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia

This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary hypercholesterolemia or mixed dyslipidemia. Period 3 will be open-label and will evaluate single dose pharmacokinetics of nicotinic acid and laropiprant components of Tredaptive.

Inclusion Criteria:

• Participant has primary hypercholesterolemia or mixed dyslipidemia (high cholesterol)
• Participant is a non-smoker

Exclusion Criteria:

• Participant has a history of chronic seizures
• Participant has a history of cancer
• Participant has a history of stomach or intestinal ulcers or any history of GI bleeding
• Participant has had major surgery, donated blood or participated in another investigational study in the past 4 weeks